NCT00722228RecruitingPhase 1/2
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
Source: ClinicalTrials.gov · Last updated 2 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with melanoma and colorectal, gastric, ovarian, breast, lung and kidney epithelial cancer. Tumor cells grown in the laboratory will be modified to make them stimulatory to the immune system, irradiated to kill them, and injected to the patient eight times at two-week intervals. This protocol is expected to prolong survival of metastatic cancer patients.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 23 Jul 2008
- Start date
- Jul 2008
- Primary completion date
- Mar 2025
- Lead sponsor
- Hadassah Medical Organization
- Diseases
- Kidney cancer, Melanoma, Lung cancer, Colorectal cancer, Gastric and esophageal cancer, Ovarian cancer
- NCT number
- NCT00722228
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 50
- From Jul 2008 to the primary completion date, Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Below 18 years of age
Other
- Women who are pregnant
- Life expectancy of less than three months
Who the study is looking for
- One of the following metastatic cancers: Melanoma, breast, ovary, colorectal, gastric, lung or kidney
- Above 18 years of age
- Failure of at least one chemotherapy protocol
- Clinical performance status of ECOG 0,1
- Absolute neutrophil count greater than 1000/mm3
- Serum ALT/AST less than three times the upper limit of normal
- Serum creatinine less than or equal to 1.6 mg/dl.
- Must be able to understand and sign the Informed Consent document
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hadassah Medical Organization Coordinator of this site? Confirm its status | Jerusalem | Israel | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.